FDA grants IDE to SpinaFX for study of Triojection

SpinaFX Medical has received the US FDA investigational device exemption (IDE) to study its Triojection therapy. The planned trial is expected to include 300 participants across two treatment arms. The study will evaluate intradiscal ozone / oxygen injection plus nerve root block compared to nerve root block alone. Credit: sweet_tomato / Shutterstock.com. SpinaFX Medical has received the US Food and Drug Administration (FDA) investigational device exemption (IDE) to study its Triojection therapy. The IDE enables SpinaFX to begin a pivotal clinical trial in the US. Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.…

Source: Medical Device Network